Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04484623
Recruitment Status : Recruiting
First Posted : July 23, 2020
Last Update Posted : October 22, 2020
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Belantamab mafodotin Drug: Pomalidomide Drug: Dexamethasone Drug: Bortezomib Phase 3

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: This is an open-label study; therefore, no blinding of treatment identity is needed.
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Actual Study Start Date : October 1, 2020
Estimated Primary Completion Date : April 11, 2022
Estimated Study Completion Date : January 1, 2027


Arm Intervention/treatment
Experimental: Arm A:Belantamab mafodotin plus Pomalidomide and Dexamethasone Drug: Belantamab mafodotin
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Drug: Pomalidomide
Immunomodulatory imide drug (IMiD)

Drug: Dexamethasone
Synthetic glucocorticoid with anti-tumor activity

Experimental: Arm B:Bortezomib plus Pomalidomide and Dexamethasone Drug: Pomalidomide
Immunomodulatory imide drug (IMiD)

Drug: Dexamethasone
Synthetic glucocorticoid with anti-tumor activity

Drug: Bortezomib
Proteasome Inhibitor




Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Up to 84 months ]
    Time from start of study treatment to the first documented disease progression or death due to any cause, whichever occurs first.


Secondary Outcome Measures :
  1. Minimal residual disease (MRD) negativity rate [ Time Frame: Up to 84 months ]
    Percentage of participants who are MRD negative by next-generation sequencing.

  2. Overall response rate (ORR) [ Time Frame: Up to 84 months ]
    Percentage of participants with a confirmed partial response or better.

  3. Complete response rate (CRR) [ Time Frame: Up to 84 months ]
    Percentage of participants with a confirmed complete response or better.

  4. Very good partial response (VGPR) or better rate [ Time Frame: Up to 84 months ]
    Percentage of participants with a confirmed VGPR or better.

  5. Duration of response (DoR) [ Time Frame: Up to 84 months ]
    Time from first documented evidence of partial response or better to date of first documented progression or death, whichever occurs first.

  6. Time to best response (TTBR) [ Time Frame: Up to 84 months ]
    Time from the start of study treatment to the first documented evidence of best response among participants who achieve partial response or better.

  7. Time to response (TTR) [ Time Frame: Up to 84 months ]
    Time from the start of study treatment to the first documented evidence of response among participants who achieve partial response or better.

  8. Time to progression (TTP) [ Time Frame: Up to 84 months ]
    Time from the start of study treatment until the first documented date of disease progression or death, whichever occurs first.

  9. Overall survival (OS) [ Time Frame: Up to 84 months ]
    Time from randomization to death due to any cause.

  10. Progression-free survival on subsequent line of therapy (PFS2) [ Time Frame: Up to 84 months ]
    Time from start of study treatment to disease progression after initiation of new anti-cancer therapy or death from any cause, whichever occurs first.

  11. Number of participants with adverse events (AEs) [ Time Frame: Up to 84 months ]
    AEs will be collected.

  12. Number of participants with serious adverse events (SAEs) [ Time Frame: Up to 84 months ]
    SAEs will be collected.

  13. Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters [ Time Frame: Up to 84 months ]
    Blood and urine samples will be collected for the assessment of hematology, clinical chemistry and urinalysis lab parameters.

  14. Number of participants with abnormal ocular findings on ophthalmic examination [ Time Frame: Up to 84 months ]
    Ophthalmic examination will assess abnormal findings.

  15. Plasma concentrations of belantamab mafodotin at indicated time points [ Time Frame: Up to 84 months ]
    Plasma concentrations of belantamab mafodotin in Arm A

  16. Plasma concentrations of total monoclonal antibody (mAb) at indicated time points [ Time Frame: Up to 84 months ]
    Plasma concentrations of total mAb in Arm A

  17. Plasma concentrations of monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) at indicated time points [ Time Frame: Up to 84 months ]
    Plasma concentrations of cys-mcMMAF in Arm A

  18. Maximum observed concentration (Cmax) for pomalidomide [ Time Frame: Up to 24 hours ]
    Pharmacokinetic analysis of pomalidomide.

  19. Time of Cmax (Tmax) for pomalidomide [ Time Frame: Up to 24 hours ]
    Pharmacokinetic analysis of pomalidomide.

  20. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) for pomalidomide [ Time Frame: Up to 24 hours ]
    Pharmacokinetic analysis of pomalidomide.

  21. Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin [ Time Frame: Up to 84 months ]
    Plasma concentrations of belantamab mafodotin ADAs in Arm A.

  22. Titers of ADAs against belantamab mafodotin [ Time Frame: Up to 84 months ]
    Titers of ADAs in Arm A.

  23. Change from Baseline in symptoms as measured by patient-reported outcome version of the common terminology criteria for adverse events (PRO-CTCAE) [ Time Frame: Baseline and up to 84 months ]
    PRO-CTCAE questionnaire assesses side effect symptoms in cancer clinical trials using a PRO-CTCAE score.

  24. Change from Baseline in impacts as measured by PRO-CTCAE [ Time Frame: Baseline and up to 84 months ]
    PRO-CTCAE questionnaire assesses side effect symptoms in cancer clinical trial. Impacts of the side effects will be assessed using PRO-CTCAE score.

  25. Change from Baseline in health related quality of life (HRQoL) as measured by European Organization for Research and Treatment of Cancer Quality of life Questionnaire 30-item core module (EORTC QLQ-C30) [ Time Frame: Baseline and up to 84 months ]
    EORTC Quality of Life questionnaire QLQ-C30 on a scale of 0-100. Lower scores correlate with worse quality of life and higher scores correlate with better quality of life.

  26. Change from Baseline in HRQoL as measured by EORTC item library 52 (IL52) [ Time Frame: Baseline and up to 84 months ]
    EORTC QLQ- 20-item Multiple Myeloma Module (MY20) questionnaire will be referred to as the EORTC IL52. Only disease symptoms domain will be assessed. A high score represents a high level of symptoms or problems.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Capable of giving signed informed consent.
  • Male or female, 18 years or older.
  • Have a confirmed diagnosis of multiple myeloma (MM) as defined by the IMWG criteria.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen and must have documented disease progression during or after their most recent therapy.
  • Must have at least 1 aspect of measurable disease defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter, or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per deciliter and an abnormal serum free light chain ratio (<0.26 or >1.65) only if participant has no measurable urine or serum M spike.
  • Have undergone autologous stem cell transplant (SCT) or are considered transplant ineligible. Participants with a history of autologous SCT may be eligible for study participation.
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrolment, except for alopecia.
  • Adequate organ system functions.
  • Male and female participants agree to abide by protocol-defined contraceptive requirements.

Exclusion Criteria:

  • Active plasma cell leukemia, symptomatic amyloidosis or active polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, and skin changes (POEMS) syndrome at the time of screening.
  • Prior allogeneic SCT.
  • Systemic anti-myeloma therapy (including chemotherapy and systemic steroids) within 14 days or five half-lives (whichever is shorter) preceding the first dose of study drug; prior treatment with a monoclonal antibody drug within 30 days of receiving the first dose of study drugs.
  • Plasmapheresis within 7 days prior to the first dose of study drug.
  • Received prior treatment with or intolerant to pomalidomide.
  • Received prior Beta cell maturation antigen (BCMA) targeted therapy.
  • Intolerant to bortezomib or refractory to bortezomib (for example; participant experienced progressive disease during treatment, or within 60 days of completing treatment, with a bortezomib-containing regimen of 1.3 mg/ m^2 twice weekly).
  • Evidence of cardiovascular risk including any of the following;

    1. Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram abnormalities including second degree (Mobitz type II) or third degree atrioventricular (AV) block.
    2. Recent history within (3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting .
    3. Class III or IV heart failure as defined by the New York Heart Association functional classification system
    4. Uncontrolled hypertension.
  • Any major surgery within the last 4 weeks.
  • Previous or concurrent invasive malignancy other than multiple myeloma, except:

    1. The disease must be considered medically stable for at least 2 years; or
    2. The participant must not be receiving active therapy, other than hormonal therapy for this disease.
  • Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
  • Evidence of active mucosal or internal bleeding.
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice.
  • Active infection requiring treatment.
  • Known human immunodeficiency virus (HIV) infection.
  • Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb) at screening or within 3 months prior to first dose of study treatment.
  • Positive hepatitis C antibody test result or positive hepatitis ribonucleic acid test result at screening or within 3 months prior to first dose of study treatment.
  • Intolerance or contraindications to anti-viral prophylaxis.
  • Presence of active renal conditions (such as infection, severe renal impairment requiring dialysis or any other condition that could affect participant's safety).
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Active or history of venous thromboembolism within the past 3 months.
  • Contraindications to or unwilling to undergo protocol-required anti-thrombotic prophylaxis.
  • Current corneal disease except for mild punctate keratopathy.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.
  • Pregnant or lactating female.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04484623


Contacts
Layout table for location contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 89904466 GSKClinicalSupportHD@gsk.com

Locations
Layout table for location information
United States, Colorado
GSK Investigational Site Recruiting
Denver, Colorado, United States, 80218
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Henning Schade         
United States, Pennsylvania
GSK Investigational Site Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Santhosh Sadashiv         
Australia, Victoria
GSK Investigational Site Recruiting
Fitzroy, Victoria, Australia, 3065
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Hang Quach         
Greece
GSK Investigational Site Recruiting
Athens, Greece, 10676
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Sosana Delimpasi         
GSK Investigational Site Recruiting
Athens, Greece, 115 28
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Meletios Dimopoulos         
Spain
GSK Investigational Site Recruiting
Pamplona, Spain, 31008
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Jesús San Miguel Izquierdo         
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT04484623    
Other Study ID Numbers: 207499
First Posted: July 23, 2020    Key Record Dates
Last Update Posted: October 22, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
URL: http://clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GlaxoSmithKline:
Belantamab Mafodotin
Relapsed/Refractory Multiple Myeloma
Pomalidomide
Dexamethasone
Bortezomib
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Bortezomib
Pomalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Immunologic Factors
Angiogenesis Inhibitors